Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 675

1.
4.

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

Diabetes Care. 1998 May;21(5):701-5.

PMID:
9589227
5.
6.

A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.

Erle G, Lovise S, Stocchiero C, Lora L, Coppini A, Marchetti P, Merante D.

Acta Diabetol. 1999 Jun;36(1-2):61-5.

PMID:
10436254
12.
13.

Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.

Cusi K, Cunningham GR, Comstock JP.

Diabetes Care. 1995 Jun;18(6):843-51.

PMID:
7555511
14.
16.

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM.

Ann Intern Med. 1994 Dec 15;121(12):928-35.

PMID:
7734015
18.

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI.

N Engl J Med. 1998 Mar 26;338(13):867-72.

20.

Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.

Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM.

Metabolism. 2004 Feb;53(2):159-64.

PMID:
14767866

Supplemental Content

Support Center